Sangamo Therapeutics (NASDAQ:SGMO) Given New $3.00 Price Target at Jefferies Financial Group

Sangamo Therapeutics (NASDAQ:SGMO) had its price target lowered by equities research analysts at Jefferies Financial Group from $7.00 to $3.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 222.58% from the company’s current price.

SGMO has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Barclays increased their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, December 13th. Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sangamo Therapeutics Price Performance

Shares of NASDAQ SGMO traded down $1.41 during midday trading on Tuesday, reaching $0.93. The company’s stock had a trading volume of 34,908,452 shares, compared to its average volume of 7,047,859. The stock has a market capitalization of $194.04 million, a P/E ratio of -1.24 and a beta of 1.15. The firm has a 50 day moving average price of $2.16 and a 200-day moving average price of $1.22. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter in the previous year, the firm posted ($0.34) EPS. On average, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SGMO. Renaissance Technologies LLC increased its holdings in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after acquiring an additional 272,123 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the last quarter. State Street Corp lifted its position in Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 145,400 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Sangamo Therapeutics by 56.3% in the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares during the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.